Articles related to ANTIDEPRESSANTS

In an analysis of 26 reviews covering 8 antidepressant classes and 22 pain conditions, no review provided a high level of evidence for the effectiveness of antidepressants for chronic pain. The strongest evidence may be for SNRIs for back pain, postoperative pain, neuropathic pain, and fibromyalgia.

Clinically significant anxiolytic and antidepressant benefits were seen in anxious depression patients after TMS in all samples, with average reductions in GAD-7 and PHQ-9 scores of 50% or more. The PHQ-9 scores for both the anxious and nonanxious depression groups improved equally. The worried group, however, scored higher both at the beginning of the study and after TMS, leading to significantly lower categorical rates of response and remission in depressive symptoms. The shift in anxiety and depressive symptoms substantially correlated among individuals who had anxious depression.

This meta analysis of antidepressants in MDD included 34 double-blind, randomized, placebo-controlled studies covering 20 antidepressants. Outcomes were 6-month relapse rates and tolerability measures. Fourteen of the agents had better relapse rates than placebo. Four — desvenlafaxine, paroxetine, venlafaxine, and vortioxetine — displayed the best efficacy and tolerability.

Pregnant women who filled prescriptions for bupropion, citalopram, escitalopram, fluoxetine, or sertraline during pregnancy (antidepressant-exposed cohort) and pregnant women who did not fill an antidepressant prescription within 90 days of the start of their pregnancy through delivery (control group) were the subjects of the study conducted by researchers from Brigham and Women’s Hospital in the United States. The main finding concerned the frequency of ADHD, autism spectrum disorder (ASD), behavioral disorder, developmental coordination disorder, developmental speech or language disorder, intellectual disability, any NDDs, and specific learning disorders among the children of the women in the study.

Some studies in children have reported a relationship between antidepressant use in pregnancy and neurodevelopment disorders after birth. In this analysis of 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies, crude results suggested up to a doubling in risk of neurodevelopmental outcomes. Significantly, however, no association was observed after balancing for confounding variables.

Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.